Lopinavir-ritonavir alone or combined with arbidol in the treatment of 73 hospitalized patients with COVID-19: A pilot retrospective study https://doi.org/10.5414/CP203861 73 patients were divided into two groups: group LR (34 cases) and group LR+Ar (39 cases), according to the antiviral… Continue reading "(25 Feb 2021) Lopinavir/r & Arbidol- did not significantly accelerate main symptom improvement"
Hydroxychloroquine with azithromycin in patients hospitalized for mild and moderate COVID-19 https://doi.org/10.1016/j.bjid.2021.101549 The active group comprised 101 (52.3%) patients using hydroxychloroquine associated with azithromycin and the control group 92 (47.7%) patients who did not take these medications. Median age was… Continue reading "(24 Feb 2021) Hydroxychloroquine & Azithromycin- ineffective in hospitalized patients with mild to moderate COVID-19"
Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: single center cohort study of 685 patients https://doi.org/10.1016/j.jtauto.2021.100086 From March 3 rd to May 7 th, 685 patients were included for analysis (58.4% males, mean age 68.9 years). Patients… Continue reading "(23 Feb 2021) Tocilizumab & methylprednisolone- showed significant impact on survival"
Efficacy and safety of Ivermectin and Hydroxychloroquine in patients with severe COVID-19. A randomized controlled trial https://www.medrxiv.org/content/10.1101/2021.02.18.21252037v1 NCT04391127–During the month of August, the admission of patients requiring hospitalization mostly encompassed cases with severe respiratory failure, so we ended the recruitment… Continue reading "(23 Feb 2021) Ivermectin & Hydroxychloroquine- neither of them decreases the number of in-hospital days"
Tocilizumab Treatment in Critically Ill Patients with COVID-19: A Retrospective Observational Study https://doi.org/10.1016/j.ijid.2021.02.057 More tocilizumab-treated patients required mechanical ventilation (44/55, 80%) compared to non-treated patients (15/41, 37%; p<0.001). Of 55 patients treated with tocilizumab, 32 (58%) were on mechanical ventilation… Continue reading "(21 Feb 2021) Tocilizumab- associated with reduced mortality"
Dexamethasone use and Mortality in Hospitalized Patients with Coronavirus Disease 2019: a Multicenter Retrospective Observational Study https://doi.org/10.1111/bcp.14784 Of 12,217 adult patients hospitalized with a positive COVID-19 PT-PCR test, 171 (1.4%) received dexamethasone orally or by intravenous perfusion during the visit.… Continue reading "(21 Feb 2021) Dexamethasone- 60 mg and 150 mg was associated with reduced mortality"
No clinical benefit of high dose corticosteroid administration in patients with COVID-19: A preliminary report of a randomized clinical trial https://www.sciencedirect.com/science/article/pii/S001429992100100X?via%3Dihub IRCT20151227025726N17- The aim of this study was to evaluate the clinical effects of dexamethasone administration in patients with mild… Continue reading "(20 Feb 2021) Dexamethasone- No clinical benefits observed"
Ivermectin shows clinical benefits in mild to moderate COVID19: A randomised controlled double-blind, dose-response study in Lagos https://doi.org/10.1093/qjmed/hcab035 We conducted a translational proof of concept (PoC) randomized, double blind placebo controlled, dose response, parallel group study of IV efficacy in… Continue reading "(19 Feb 2021) Ivermectin-Days to COVID negativity was significantly and dose dependently reduced by IV"
Impact of hydroxychloroquine on disease progression and ICU admissions in patients with SARS-CoV-2 infection https://doi.org/10.1093/ajhp/zxab056 A retrospective, observational, cohort study was conducted to determine selected treatment outcomes in 336 patients hospitalized with COVID-19 at an acute care, community hospital in… Continue reading "(19 Feb 2021) Hydroxychloroquine- associated with increased risks of ICU admission"
Effectiveness of anakinra for tocilizumab-refractory severe COVID-19. A single centre retrospective comparative study https://doi.org/10.1016/j.ijid.2021.02.041 A prospective cohort of patients with COVID19 pneumonia who received anakinra as salvage therapy after failure of tocilizumab were compared (1:1) to selected controls in a… Continue reading "(17 Feb 2021) Anakinra-not useful to improve the prognosis of patients with tocilizumab-refractory severe COVID-19"
